BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Submitted by Anonymous on

--BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that updated data from the ongoing Phase 1/ 2 SOLARA trial describing anti-tumor...

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

Submitted by Anonymous on

AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY ®, an oral irreversible epidermal growth factor receptor inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired...

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

Submitted by Anonymous on

--HUTCHMED Limited today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer whose tumors harbor epidermal growth factor receptor mutation and MET overexpression. Dr Weiguo Su,...

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Submitted by Anonymous on

--HUTCHMED Limited today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop...

Baili Tianheng (688506.SH): The Phase III clinical trial of Yizekang for maintenance therapy following concurrent chemoradiotherapy in unresectable EGFR-mutant non-small cell lung cancer has completed enrollment of the first subject.

Submitted by Anonymous on

Baili Tianheng (688506.SH) announced that the first patient has been enrolled in the Phase III randomized controlled clinical trial (PANKU-Lung08). This trial compares BL-B01D1 combined with osimertinib versus osimertinib monotherapy for the treatment of patients with unresectable Stage III EGFR-mutant...

Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report

Submitted by Anonymous on

Abstract Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved outcomes for patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, acquired resistance remains a critical clinical challenge.Here, we present the case of a 62-year-old male with...

Subscribe to Newsfeed